RNA insiders file Form 144 for 25,000-share sale valued at $1.2M

Rhea-AI Filing Summary

Avidity Biosciences (RNA) filed a Form 144 reporting the proposed sale of 25,000 shares of common stock through Morgan Stanley Smith Barney LLC on NASDAQ with an aggregate market value of $1,195,500. The filing shows the shares were acquired and paid for on 08/28/2025 via exercise of stock options from the issuer, and the filer reports no securities sold in the past three months. The notice includes the filer’s representation that they are not aware of undisclosed material adverse information and contains the standard signature and certification language.

Positive

• Filed under Rule 144 with broker details and transaction specifics
• Securities were acquired via exercise of stock options with cash payment on 08/28/2025
• No other securities sold by the filer in the past three months
• Filer includes required certification regarding material nonpublic information

Negative

• None.

Insights

Securities Analyst

TL;DR: Small, routine insider-option exercise and proposed sale; appears procedural and compliant with Rule 144.

The filing documents an insider exercise of stock options and a contemporaneous proposed sale of 25,000 shares valued at $1,195,500 brokered through Morgan Stanley Smith Barney LLC on NASDAQ. The acquisition and payment date are the same (08/28/2025), indicating the shares stem from option exercise rather than a prior secondary purchase. The filer reports no other sales in the last three months, and the filing includes the required attestations about material nonpublic information. Given the size relative to total outstanding shares (128,653,337), this appears to be a routine compliance notice rather than a material corporate event.

Corporate Governance Expert

TL;DR: Filing meets disclosure requirements; includes standard representations and broker details, supporting transparency.

The Form 144 supplies the broker name and address, exact share count, aggregate market value, outstanding share count, and acquisition mechanics (exercise of stock options, cash payment). It also includes the filer’s certification regarding undisclosed material adverse information. These elements satisfy typical Rule 144 disclosure expectations and provide investors and regulators with necessary transaction detail for oversight.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	25000	1195500.00	128653337	08/28/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/28/2025	Exercise of Stock Options	Issuer			25000	08/28/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What did Avidity Biosciences (RNA) report on this Form 144?

The filing reports a proposed sale of 25,000 common shares via Morgan Stanley Smith Barney LLC with an aggregate market value of $1,195,500, to be sold on 08/28/2025 on NASDAQ.

How were the 25,000 shares acquired according to the Form 144?

The shares were acquired on 08/28/2025 through the exercise of stock options from the issuer and paid for in cash on that date.

Does the filing show any other sales by the filer in the past three months?

The Form 144 states "Nothing to Report" for securities sold during the past three months.

Which broker is handling the proposed sale?

The sale is to be handled by Morgan Stanley Smith Barney LLC Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004.

What is the total number of Avidity Biosciences shares outstanding reported in the filing?

The filing lists 128,653,337 shares outstanding.